Eli Lilly Partners with Nvidia to Invest $1 Billion in AI Drug Discovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- AI Innovation Lab: Eli Lilly partners with Nvidia to establish an innovation lab in the San Francisco Bay Area, with a joint investment of up to $1 billion over five years aimed at accelerating drug discovery and improving the success rate of new drug development, thereby enhancing the company's competitive edge in the pharmaceutical industry.
- Sales Growth: Eli Lilly's weight management drug Zepbound became the best-selling drug globally in Q3, driving a 54% year-over-year revenue increase to $17.6 billion, showcasing its strong market influence and future growth potential.
- Diversified Pipeline: Eli Lilly is focused on reducing reliance on its core therapeutic areas by launching new drugs like Ebglyss, Jaypirca, and Kisunla, with expectations to introduce more products over the next five years to further enrich its portfolio and strengthen market competitiveness.
- Dividend Growth Potential: Eli Lilly has increased its dividend by 103.5% over the past five years, reflecting its robust free cash flow and commitment to shareholder returns, making it an attractive choice for investors seeking both growth and dividends.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1078 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1032.970
Low
800.00
Averages
1078
High
1300
Current: 1032.970
Low
800.00
Averages
1078
High
1300
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
